| Godina | Naslov | Autor(i) | Tip rezultata | Mp-kat. |
| 2023 | Tumor Treating Field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study | Leal, Ticiana; ...; Andric, Zoran G   ; ...; (broj, koautora 20) | Konferencijski rad | |
| 2023 | Impact of TTFields therapy on global and functional health-related quality of life (HRQoL) in metastatic non-small cell lung cancer (mNSCLC) from the pivotal LUNAR study | Kotecha, R; ...; Andric, Zoran G ; ...; (broj, koautora 20) | Konferencijski rad | |
| 2023 | Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study | Leal, Ticiana A; ...; Andric, Zoran G ; ...; (broj, koautora 25) | Naučni članak | 21a+M21a+ - Vodeći međunarodni časopis kategorije M21a+ |
| 2023 | HERIZON: A phase II study of HER-Vaxx (IMU-131), a HER2targeting peptide vaccine plus standard of care chemotherapy in patients with HER2+advanced stomach cancer - Dose-dependent anti-cancer antibodies correlating with improved clinical outcome | Tobias, Joshua; Kundi, Michael; Garner-Spitzer, E; Zielinski, Christoph; Maglakelidze, Marina; Andric, Zoran G ; Petrovic, Z; Nagarkar, R; Chawla, T; Chong, LO;
Nixon, B; Yavrom, S; Ede, NJ; Wiedermann, Ursula;
| Konferencijski rad | |
| 2022 | Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial | Verschraegen, Claire; Andric, Zoran G ; Moiseenko, Fedor; Makharadze, Tamta; Shevnya, Sergii; Oleksiienko, Alona; Ruiz, Eduardo Yanez; Kim, SungHyun; Ahn, KeumYoung; Park, TaeHong;
Park, Sijin; Ju, Hana; Ohe, Yuichiro;
| Naučni članak | 21aM21a - Vodeći međunarodni časopis kategorije M21a |
| 2022 | Overweight and obesity in polycystic ovary syndrome: Association with inflammation, oxidative stress and dyslipidaemia | Perović-Blagojević, Iva; Vekić, Jelena ; Macut, Đuro ; Ignjatović, Svetlana ; Miljković-Trailović, Milica ; Zeljković, Aleksandra ; Spasojević-Kalimanovska, Vesna ; Božić-Antić, Ivana ; Bjekić-Macut, Jelica ; Kastratović-Kotlica, Biljana ;
Andrić, Zoran ; Ilić, Dušan; Kotur-Stevuljević, Jelena ; | Naučni članak | 22M22 - Međunarodni časopis kategorije M22 |
| 2022 | Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2 | Goel, Shom; Tan, Antoinette R; Rugo, Hope S; Aftimos, Philippe; Andric, Zoran G ; Beelen, Andrew Paul; Zhang, Jingshan; Yi, John S; Malik, Rajesh K; O'Shaughnessy, Joyce | Naučni članak | 22M22 - Međunarodni časopis kategorije M22 |
| 2022 | Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial | Peters, Solange; ...; Andric, Zoran G ; ...; (broj, koautora 26) | Naučni članak | 21a+M21a+ - Vodeći međunarodni časopis kategorije M21a+ |
| 2022 | Randomized phase III study comparing the efficacy and safety of CT-P16, a new biosimilar, to reference bevacizumab (Avastin (R)) in patients with metastatic or recurrent non-small cell lung cancer (NSCLC) | Ohe, Yuichiro; ...; Andric, Zoran G ; ...; (broj, koautora 17) | Konferencijski rad | |
| 2022 | 1-year follow-up of a phase III study to compare efficacy and safety of a bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer | Verschraegen, Claire; Andric, Zoran G ; ...; (broj, koautora 20) | Konferencijski rad | |
| 2022 | HERIZON overall survival results: A study of IMU-131, a HER2 targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2 overexpressing metastatic or advanced gastric/GEJ cancer | Maglakelidze, Marina; Ryspayeva, D; Andric, Zoran G ; Petrovic, Zeljko M; Bulat, IV; Nikolic, Ivan V ; Chawla, T; Nagarkar, R; Wiedermann, Ursula; Blumenstein, BA;
Chong, LMO; Ede, NJ; Nixon, B; Good, AJ;
| Konferencijski rad | |
| 2022 | Avelumab vs Chemotherapy for First-line Treatment of Advanced PD-L1+NSCLC: Primary Analysis from JAVELIN Lung 100 | Reck, M; ...; Andric, Zoran G ; ...; (broj, koautora 19) | Konferencijski rad | |
| 2022 | Perioperative bevacizumab in the treatment of colorectal cancer in patients with liver metastases | Nikolić, Ivan ; Manojlović, Nebojša ; Andrić, Zoran ; Radosavljević, Davorin ; Ristić, Marija; Kovčin, Vladimir | Naučni članak | 51M51 - Vodeći nacionalni časopis kategorije M51 |
| 2022 | Clinical potential of circulating tumor DNA (ctDNA)-based molecular response (MR) and baseline blood-based tumor mutational burden (bTMB) for monitoring response to firstline (1L) chemoimmunotherapy in advanced squamous non-small cell lung cancer (sqNSCLC | Ciardiello, F; Feng, Z; Smith, NR; Andric, Zoran G ; Shell, S; Yablonovitch, A; Guezel, G; Scheuenpflug, J | Konferencijski rad | |
| 2021 | Trial in progress: A phase 3, randomized, double-blind trial of trilaciclib versus placebo in patients receiving first- or second-line gemcitabine and carboplatin for locally advanced unresectable or metastatic triple-negative breast cancer (PRESERVE 2). | Goel, Shom; O'Shaughnessy, Joyce; Tan, Antoinette R; Milev-Krastev, Boris; Rugo, Hope S; Aftimos, Philippe Georges; Yardley, Denise A; Andric, Zoran G ; Wolfgang, Curt Douglas; Sorrentino, Jessica;
Tao, Wenli; Beelen, Andrew Paul; Malik, Rajesh K; Jain, Sarika;
| Konferencijski rad | |
| 2021 | 565Tip A phase I/II dose-escalation and expansion study of ZN-c5, an oral selective estrogen receptor degrader (SERD), as monotherapy and in combination with palbociclib in patients with advanced estrogen receptor (ER)+/HER2-breast cancer | Abramson, V; ...; Andric, Zoran G ; Milovic-Kovacevic, Marijana M ; Trifunovic, Jasna D; ...; (broj, koautora 16) | Konferencijski rad | |
| 2021 | Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC | Jassem, Jacek; ...; Andric, Zoran G ; ...; (broj, koautora 19) | Naučni članak | 21a+M21a+ - Vodeći međunarodni časopis kategorije M21a+ |
| 2021 | First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC) | Andric, Zoran G ; ...; Stojanovic, Goran; Petrovic, Marina D ; ...; (broj, koautora 20) | Konferencijski rad | |
| 2021 | A Phase 1b/2 Open-Label Study with Randomization in Phase 2 of Imu-131 Her2/Neu Peptide Vaccine Plus Standard of Care Chemotherapy in Patients with Her2/Neu Overexpressing Metastatic Or Advanced Adenocarcinoma of the Stomach Or Gastroesophageal Junction. | Maglakelidze, Marina; ...; Andric, Zoran G ; Nikolic, Ivan V ; ...; Radosavljevic, Davorin Z ; Petrovic, Zoran; ...; (broj, koautora 17) | Konferencijski rad | |
| 2021 | HERIZON: A phase 1B/2 open-label study of imu-131 HER2/neu peptide vaccine PLUS standard of care chemotherapy with randomization in phase 2 in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal j | Laeufle, Rita; ...; Andric, Zoran G ; ...; Nikolic, Ivan V ; ...; Radosavljevic, Davorin Z; ...; (broj, koautora 16) | Konferencijski rad | |
Andrić, Zoran
